1023 related articles for article (PubMed ID: 29381780)
1. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
2. Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K; Kumar R
Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
[TBL] [Abstract][Full Text] [Related]
3. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
Takashi Y; Kawanami D; Fukumoto S
Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
[TBL] [Abstract][Full Text] [Related]
4. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
5. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S
J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
[TBL] [Abstract][Full Text] [Related]
6. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
Kinoshita Y
Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
8. [Bone and Calcium Research Update 2015. Novel treatment for FGF23-related hypophosphatemic diseases].
Fukumoto S
Clin Calcium; 2015 Jan; 25(1):37-44. PubMed ID: 25530521
[TBL] [Abstract][Full Text] [Related]
9. A PAI-1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D-resistant rickets model mouse.
Qian C; Ito N; Tsuji K; Sato S; Kikuchi K; Yoshii T; Miyata T; Asou Y
FEBS Open Bio; 2024 Feb; 14(2):290-299. PubMed ID: 38050660
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of PHEX Mutations and FGF23 Profiles in a Taiwanese Cohort With X-Linked Hypophosphatemia Including 102 Patients.
Su PH; Yu JS; Wu YZ; Tsai YS; Lo FS; Lin JL; Chao MC; Hsu CC; Ke YY; Chiu PC; Chen JC; Huang YH; Lin SP; Chou YY; Ting WH; Wang SY; Chiu CF; Huang YC; Hsiao HP; Lin CH; Wang CH; Bau DT; Lin CY
In Vivo; 2024; 38(1):341-350. PubMed ID: 38148081
[TBL] [Abstract][Full Text] [Related]
13. [Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia].
Kinoshita Y; Fukumoto S
Clin Calcium; 2014 Aug; 24(8):1217-22. PubMed ID: 25065874
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
16. Congenital Conditions of Hypophosphatemia Expressed in Adults.
Marcucci G; Brandi ML
Calcif Tissue Int; 2021 Jan; 108(1):91-103. PubMed ID: 32409880
[TBL] [Abstract][Full Text] [Related]
17. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
[TBL] [Abstract][Full Text] [Related]
18. Advances in understanding of phosphate homeostasis and related disorders.
Michigami T
Endocr J; 2022 Aug; 69(8):881-896. PubMed ID: 35831119
[TBL] [Abstract][Full Text] [Related]
19. Approach to Hypophosphatemic Rickets.
Ackah SA; Imel EA
J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
[TBL] [Abstract][Full Text] [Related]
20. Rickets guidance: part II-management.
Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
